RxDoctor Payments Data

Tonda Bradshaw, DO

Internal Medicine · Yucaipa, CANPI 1760574123

Payments from drug & device makers

$769in general payments, 2019–2025

Across 52 payments — averaging $14.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$303
  • Abbott$67
  • AstraZeneca$62
  • GSK$56
  • Mannkind Corporation$49
  • Sanofi-aventis U.S. LLC$44
  • plus $189 from 8 others

What the payments were for

  • Food & beverage$769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$769 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$30,574
Medicare patients
123
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate144$156,112
EliquisApixaban132$112,622
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$31,215
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr57$29,264
JardianceEmpagliflozin26$29,149
Stiolto RespimatTiotropium Br/Olodaterol Hcl55$27,019
Invega SustennaPaliperidone Palmitate12$26,260
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog33$24,305
Lantus SolostarInsulin Glargine,hum.Rec.Anlog113$22,339
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog50$22,126
FarxigaDapagliflozin Propanediol13$21,133
TrulicityDulaglutide18$21,017
Spiriva RespimatTiotropium Bromide21$16,826
XareltoRivaroxaban16$14,958
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog24$13,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$38$72,994102 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$56$69,453119 claims
Johnson & JohnsonInvega Sustenna, Xarelto$38$41,21928 claims
AstraZenecaFarxiga, Symbicort$62$27,02928 claims
AbbVieSynthroid$303$5,02959 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$30$4,41417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Yucaipa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →